Achal Patel, Mercer University College of Pharmacy
Venous thromboembolism (VTE) is the third leading cause of vascular diagnosis following heart attack and stroke.  It is categorized into two types: deep vein thrombosis (DVT) and pulmonary embolism (PE). Venous thromboembolism affects men and women of all ages, and patients that are immobilized are at a higher risk. 
The Chest Guidelines recommend anticoagulants for up to two weeks after hospital discharge.  However, the risk of a VTE remains increased for at least a month. Therefore, Bevyxxa® (betrixaban), which is a direct and selective factor Xa inhibitor, was tested for extended-duration therapy for thromboprophylaxis in acutely ill medical patients.